Cargando…
Machine learning profiles of cardiovascular risk in patients with diabetes mellitus: the Silesia Diabetes-Heart Project
AIMS: As cardiovascular disease (CVD) is a leading cause of death for patients with diabetes mellitus (DM), we aimed to find important factors that predict cardiovascular (CV) risk using a machine learning (ML) approach. METHODS AND RESULTS: We performed a single center, observational study in a coh...
Autores principales: | Kwiendacz, Hanna, Wijata, Agata M., Nalepa, Jakub, Piaśnik, Julia, Kulpa, Justyna, Herba, Mikołaj, Boczek, Sylwia, Kegler, Kamil, Hendel, Mirela, Irlik, Krzysztof, Gumprecht, Janusz, Lip, Gregory Y. H., Nabrdalik, Katarzyna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464339/ https://www.ncbi.nlm.nih.gov/pubmed/37620935 http://dx.doi.org/10.1186/s12933-023-01938-w |
Ejemplares similares
-
Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project
por: Nabrdalik, Katarzyna, et al.
Publicado: (2023) -
Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials
por: Nabrdalik, Katarzyna, et al.
Publicado: (2022) -
Low Quantitative Blush Evaluator score predicts larger infarct size and reduced left ventricular systolic function in patients with STEMI regardless of diabetes status
por: Nabrdalik, Katarzyna, et al.
Publicado: (2023) -
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach
por: Drożdż, Karolina, et al.
Publicado: (2022) -
Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study
por: Nabrdalik-Leśniak, Diana, et al.
Publicado: (2021)